Skip Navigation

Cardiovascular Research 1998 40(1):138-145; doi:10.1016/S0008-6363(98)00112-6
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tracey, W.R.
Right arrow Articles by Hill, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tracey, W.R.
Right arrow Articles by Hill, R. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation

W.Ross Traceya,*, William Mageea, Hiroko Masamuneb, Joseph J. Oleyneka and Roger J. Hilla

aDepartment of Cardiovascular and Metabolic Diseases, Central Research Division, Pfizer Inc., Groton, CT 06340, USA
bDepartment of Medicinal Chemistry, Central Research Division, Pfizer Inc., Groton, CT 06340, USA

* Corresponding author. Tel.: +1 (860) 441 1761; Fax: +1 (860) 441 5719; E-mail: w_ross_tracey@groton.pfizer.com

Objective: The aim of this study was to characterize the adenosine A3 receptor agonist, N6-(3-chlorobenzyl)-5'-N-methylcarboxamidoadenosine (CB-MECA), evaluate its ability to reduce myocardial ischemia/reperfusion injury and determine the role of KATP-channel activation in A3 receptor-mediated cardioprotection. Methods: Binding affinities and adenylate cyclase inhibition were examined in CHO cells expressing rabbit recombinant adenosine A1 or A3 receptors. Infarct size (normalized for area-at-risk;% IA/AAR) was measured in buffer-perfused rabbit hearts exposed to 30-min regional ischemia and 120 min of reperfusion. Results: CB-MECA was 100-fold selective for A3 vs. A1 receptors (A3 Ki: 1 nM; A1 Ki: 105 nM). Five-min perfusion with CB-MECA before ischemia/reperfusion elicited a concentration-dependent reduction in infarct size (EC50: 0.3 nM). The CB-MECA-dependent cardioprotection (control: 58±2; CB-MECA: 21±3% IA/AAR) was unchanged by an A1-selective concentration of the antagonist, BWA1433, but was completely prevented (P<0.05) by a nonselective (A1/A3) concentration (55±6% IA/AAR). The KATP channel inhibitors, glibenclamide and 5-HD, had no effect on control infarct size, yet significantly (P<0.05) blunted the CB-MECA-dependent cardioprotection (glibenclamide: 49±6; 5-HD: 58±4% IA/AAR). Conclusions: CB-MECA is a novel 100-fold A3 receptor-selective agonist which should prove useful for elucidating A3-dependent mechanisms in the rabbit heart. Selective stimulation of adenosine A3 receptors with CB-MECA reduces myocardial ischemia/reperfusion injury via a mechanism which involves activation of KATP channels.

KEYWORDS Rabbit; Heart; Adenosine; Infarction; KATP channel; Preconditioning; Receptors; Reperfusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach
The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z.-D. Ge, J. N. Peart, L. M. Kreckler, T. C. Wan, M. A. Jacobson, G. J. Gross, and J. A. Auchampach
Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] Reduces Ischemia/Reperfusion Injury in Mice by Activating the A Adenosine Receptor
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1200 - 1210.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. R. Morrison, B. Teng, P. J. Oldenburg, L. C. Katwa, J. B. Schnermann, and S. J. Mustafa
Effects of targeted deletion of A1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes
Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1875 - H1882.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Willems, K. J. Ashton, and J. P. Headrick
Adenosine-mediated cardioprotection in the aging myocardium
Cardiovasc Res, May 1, 2005; 66(2): 245 - 255.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. R. Tracey, J. L. Treadway, W. P. Magee, J. C. Sutt, R. K. McPherson, C. B. Levy, D. E. Wilder, L. J. Yu, Y. Chen, R. M. Shanker, et al.
Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1177 - H1184.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. R. Tracey, W. P. Magee, J. J. Oleynek, R. J. Hill, A. H. Smith, D. M. Flynn, and D. R. Knight
Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury
Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2780 - H2787.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. A. Auchampach, Z.-D. Ge, T. C. Wan, J. Moore, and G. J. Gross
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H607 - H613.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and G. J. Gross
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H81 - H89.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Peart, L. Willems, and J. P. Headrick
Receptor and non-receptor-dependent mechanisms of cardioprotection with adenosine
Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H519 - H527.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
R. M. Mentzer Jr., M. S. Jahania, and R. D. Lasley
Myocardial Protection
Card. Surg. Adult, January 1, 2003; 2(2003): 413 - 438.
[Full Text]


Home page
Circ. Res.Home page
R. G. Black Jr, Y. Guo, Z.-D. Ge, S. S. Murphree, S. D. Prabhu, W. K. Jones, R. Bolli, and J. A. Auchampach
Gene Dosage-Dependent Effects of Cardiac-Specific Overexpression of the A3 Adenosine Receptor
Circ. Res., July 26, 2002; 91(2): 165 - 172.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. J. Cerniway, Z. Yang, M. A. Jacobson, J. Linden, and G. P. Matherne
Targeted deletion of A3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1751 - H1758.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. L. Kilpatrick, P. Narayan, R. M. Mentzer Jr., and R. D. Lasley
Adenosine A3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX
Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H847 - H853.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
T. Reffelmann, E. C. Skobel, H. Kammermeier, P. Hanrath, and E. R. Schwarz
Activation of ATP-Sensitive Potassium Channels in Hypoxic Cardiac Failure Is not Mediated by Adenosine-1 Receptors in the Isolated Rat Heart
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 189 - 200.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
R. Zucchi, G. Yu, S. Ghelardoni, F. Ronca, and S. Ronca-Testoni
A3 adenosine receptor stimulation modulates sarcoplasmic reticulum Ca2+ release in rat heart
Cardiovasc Res, April 1, 2001; 50(1): 56 - 64.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Takano, R. Bolli, R. G. Black Jr, E. Kodani, X.-L. Tang, Z. Yang, S. Bhattacharya, and J. A. Auchampach
A1 or A3 Adenosine Receptors Induce Late Preconditioning Against Infarction in Conscious Rabbits by Different Mechanisms
Circ. Res., March 16, 2001; 88(5): 520 - 528.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. McCully, Y. Toyoda, M. Uematsu, R. D. Stewart, and S. Levitsky
Adenosine-enhanced ischemic preconditioning: adenosine receptor involvement during ischemia and reperfusion
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H591 - H602.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
B. O'Rourke
Myocardial KATP Channels in Preconditioning
Circ. Res., November 10, 2000; 87(10): 845 - 855.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. HASKÓ, D. G. KUHEL, J.-F. CHEN, M. A. SCHWARZSCHILD, E. A. DEITCH, J. G. MABLEY, A. MARTON, and C. SZABÓ
Adenosine inhibits IL-12 and TNF-{alpha} production via adenosine A2a receptor-dependent and independent mechanisms
FASEB J, October 1, 2000; 14(13): 2065 - 2074.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. R. Tracey, W. P. Magee, C. A. Ellery, J. T. MacAndrew, A. H. Smith, D. R. Knight, and P. J. Oates
Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury
Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1447 - H1452.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Hoque, M. A. Cook, and M. Karmazyn
Inhibition of alpha 1-Adrenergic-Mediated Responses in Rat Ventricular Myocytes by Adenosine A1 Receptor Activation: Role of the KATP Channel
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 770 - 777.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. E. Jordan, V. H. Thourani, J. A. Auchampach, J. A. Robinson, N.-P. Wang, and J. Vinten-Johansen
A3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury
Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1895 - H1905.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.